₹ 1,124.88 Cr
2.26%
BSE Healthcare TRI
INF789F01695
5000.0
1000.0
500
Mr. Kamal Gada FM 1,Not Applicable FM 2,Not Applicable FM 3
| Fund Performance | 1Y (%) | 3Y (%) | 5Y (%) |
|---|---|---|---|
| UTI Healthcare Fund - Regular Plan - Growth Option | 3.97 | 23.65 | 17.4 |
| Benchmark | - | - | - |
Equity
Debt
Others
The primary objective of the scheme is to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector. However, there can be no assurance or guarantee that the investment objective of the scheme would be achieved.
| Company | Holdings (%) |
|---|---|
| SUN PHARMACEUTICAL INDUSTRIES LTD. EQ NEW F.V. RE.1/- | 9.77 |
| AJANTA PHARMA LIMITED EQ NEW FV RS. 2/- | 6.25 |
| LUPIN LIMITED EQ NEW F.V. RS.2/- | 5.58 |
| GLENMARK PHARMACEUTICALS LIMITED EQ NEW FV RE.1/- | 4.12 |
| CIPLA LIMITED EQ NEW FV RS.2/- | 3.74 |
| PROCTER & GAMBLE HEALTH LIMITED EQ | 3.67 |
| GLAND PHARMA LIMITED EQ NEW FV Re.1/- | 3.65 |
| APOLLO HOSPITALS ENTERPRISE LIMITED EQ NEW F.V. RS.5/- | 3.62 |
| Dr. Reddys Laboratories Ltd | 3.57 |
| ALKEM LABORATORIES LIMITED EQ | 3.52 |
| Sector | Holdings (%) |
|---|---|
| Healthcare | 98.12 |